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ABSTRACT
Objectives: The objectives of this study were to evaluate the effects of telmisartan on plasma interleukin (IL)-6 and C-reactive protein (CRP) levels in 
monosodium glutamate (MSG)-induced obesity in Wistar albino rats.
Methods: MSG at the dose of 500 mg/kg body weight is dissolved in distilled water and administered for 22 days. On the 9th day, telmisartan 7.5 mg/kg 
body weight is administered. After completion of experiment, body weight and biochemical parameters such as plasma IL-6 and CRP levels are 
measured using enzyme-linked immunosorbent assay.
Results: Telmisartan significantly decreased plasma IL-6 and CRP levels in MSG-treated obese rats.
Conclusion: Telmisartan, probably through its peroxisome proliferator-activated receptor-γ agonistic activity, produces significant anti-obesity 
effects in rats and may help in treating obese patients with metabolic syndrome.
Keywords: Monosodium glutamate, Telmisartan, Interlukin-6, C-reactive protein.
INTRODUCTION
Obesity is a chronic and progressive disease that is rapidly increasing in 
prevalence. It is a condition characterized by abnormal or excessive fat 
deposition that poses a risk to health. In general, the crude population 
measure to obesity is body mass index (BMI); it is persons weight (in kg) 
divided by square of his/her height (in m). A person with a BMI of 30 
or more is generally considered obese. Annually, obesity is responsible 
for 2.8 million deaths and 35.8 million disability-adjusted life-years in 
population worldwide [1].
Obesity is associated with cardiovascular morbidity, hypertension, 
dyslipidemia osteoarthritis, type 2 diabetes mellitus, and depression 
and increases the prevalence of cancer [2,3]. Modern anti-obesity drugs 
produce severe side effects so the need for reliable and effective drugs is in 
demand. For safer and effective alternative, weight management requires 
a better understanding of the biology of appetite and metabolism [4]. 
Monosodium glutamate (MSG), also known as Ajinomoto, widely used as 
a taste enhancer which is a sodium salt of glutamic acid [5]. MSG is found 
in dairy products, fish, mushroom, and tomatoes and used in variety of 
food products such as processed food and snacks [6]. MSG at the dose of 
500 mg/kg body weight is found to produce obesity in rats which serve 
as an experimental obesity model [7]. Significant elevation in plasma 
interleukin (IL)-6 and C-reactive protein (CRP) levels in obese subjects 
in proportion to the degree of adiposity suggests that they may play a 
major role in the pathogenesis of obesity [8,9].
METHODS
MSG was procured from Sisco Laboratories Pvt. Ltd., India. IL-6 and 
CRP enzyme-linked immunosorbent assay (ELISA) kits were purchased 
from Krishgen Pvt., Ltd., India and standard telmisartan 40 mg tablets 
(Telma 40) from Glenmark Pharmaceuticals Ltd., India.
Female rats of 3 months old (250–300 g) were used for the study, after 
obtaining permission from the Institutional Animal Ethics Committee 
(115/1999) K. S. Hegde Medical Academy, Mangalore.
They were kept in a standard laboratory environment with laboratory 
food and water ad libitum.
p<0.05 was considered as statistically significant.
The animals were grouped and administered drugs as follows (n=6 
each):
•	 Group 1 (Control – C): Distilled water (1.5 ml, P.O)
•	 Group 2 (Positive control – PC): MSG (500 mg/kg) orally for 21 days
•	 Group 3 (Control + Telmisartan – C+T): Telmisartan (5 mg/kg) started 
on the 9th day and continued until 21st day
•	 Group 4 (Positive control + Telmisartan – PC+T): Telmisartan 
(5 mg/kg) started on the 9th day and continued till the 21st day.
The MSG and telmisartan were administered orally after dissolving in 
distilled water. The recommended dose of telmisartan in a human was 
used to calculate the dose for experimental animal. The selection dose 
of telmisartan used was based on a previous study.
On the 23rd day, blood was drawn from the tail vein and plasma was 
subjected for analysis.
IL-6 levels estimation
IL-6 was quantified by ELISA according to the manufacturer’s 
instructions (Krishgen, India). The IL-6 concentration in given blood 
samples with different treatment groups was estimated using the 
calibration curve provided with the kit [10].
C-RP estimation
C-RP was quantified by ELISA according to the manufacturer’s 
instructions (Krishgen, India). The C-RP concentration in given blood 
samples with different treatment groups was estimated using the 
calibration curve provided with the kit [11].
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 
5.0. One-way analysis of variance was performed followed by 
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The plasma IL-6 levels were significantly increased in positive control 
(MSG) group when compared to control (Fig. 1). The intervention 
groups treated with telmisartan showed a significant decrease in 
plasma IL-6 levels and there were no significant changes in telmisartan 
alone treated groups.
Plasma CRP levels
The plasma CRP levels were significantly increased in the positive 
control group (MSG) indicating inflammation (Fig. 2). The intervention 
groups treated with telmisartan, both showed a significant decrease in 
plasma CRP levels, and there are no significant changes in telmisartan 
alone treated groups.
DISCUSSION
Obesity is widely associated with other disorders such as diabetes 
mellitus, hypertension, hyperlipidemia, and also cancer [12]. Obese 
people are more prone to develop insulin resistance when compared to 
normal [13]. It has also been observed in studies that obesity leads to 
premature aging due to telomere attrition [14]. Therefore, prevention 
and treatment of obesity plays a key role in the management of its 
associated disorders and its complications.
In the present study, anti-obesity effects of telmisartan on MSG-induced 
obesity were evaluated using the estimation of plasma IL-6 and CRP 
levels by ELISA of female Wistar albino rats. The majority of drugs used 
in anti-obesity treatment in pipeline are known to cause severe adverse 
effects, thus decreasing the compliance of the treatment [15]. Since 
inflammation is associated with obesity estimation of plasma, IL-6 and 
CRP levels play a key role in understanding the effect of drugs in the 
management of obesity [16].
Recent studies indicate the role of IL-6 and CRP as an inflammatory 
marker in obesity; therefore, drugs which decrease IL-6 and CRP 
levels help in the management of obesity [17]. In the study, telmisartan 
antagonized the inflammation-mediated obesity induced by feeding 
mice with high-fat diet [18]. Telmisartan acts as an agonist of 
peroxisome proliferator-activated receptor-δ pathway which provides 
protection against inflammation associated with obesity which could 
be the possible mechanism behind its anti-obesity effects [19]. Recent 
evidence suggests that the structure of telmisartan pleiotropic effects 
is superior to other sartans which modulate the binding of fat to the 
adipose tissue. Its pharmacokinetic profile also suggests that due to 
high lipophilicity, it enters the adipocyte and prevents the accumulation 
of lipids droplets, thus preventing the activation of inflammatory 
cytokines [20].
Interestingly, several other studies support the role of CRP and IL-6 
levels changes in obesity, and the current study helps in providing 
additional evidence in employing telmisartan as a potential drug in 
prevention and management of obesity [21-23].
CONCLUSION
Telmisartan has shown a significant decrease in reducing plasma 
IL-6 and CRP levels in MSG-treated obese groups, thereby decreasing 
inflammation associated with obesity. However, further studies, 
including the evaluation of its effect on the biochemical, molecular, and 
cellular pathways, are required to establish its role as an anti-obesity 
drug.
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